Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Edelman

Showing results (71-80 of 186) with videos related to

Pageof 19
Sort By:
Annals of Internal Medicine|March 29, 2020
A War on Two Fronts: Cancer Care in the Time of COVID-19Alexander Kutikov, David S Weinberg, Martin J Edelman, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinomaPhilip C Mack, David R Gandara, Alvin H Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancerMartin J Edelman, Ruth Smith, Petr Hausner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304Martin J Edelman, Lydia Hodgson, Paula Y Rosenblatt, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2008
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cellsMinu K Srivastava, Jacobus J Bosch, James A Thompson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 1, 2012
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lungMohan Suntharalingam, Rebecca Paulus, Martin J Edelman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2011
Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancerMartin J Edelman, Gregory Otterson, Joseph Leach, et al.
The Annals of Thoracic Surgery|October 7, 2004
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancerJoshua R Sonett, Mohan Suntharalingam, Martin J Edelman, et al.
Clinical Lung Cancer|October 16, 2012
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung CancerDavid R Spigel, Martin J Edelman, Tony Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|March 30, 2010
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancerJoseph Treat, Martin J Edelman, Chandra P Belani, et al.
Pageof 19

Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
Annals of Internal Medicine|March 29, 2020
A War on Two Fronts: Cancer Care in the Time of COVID-19Alexander Kutikov, David S Weinberg, Martin J Edelman, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinomaPhilip C Mack, David R Gandara, Alvin H Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancerMartin J Edelman, Ruth Smith, Petr Hausner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304Martin J Edelman, Lydia Hodgson, Paula Y Rosenblatt, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2008
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cellsMinu K Srivastava, Jacobus J Bosch, James A Thompson, et al.
International Journal of Radiation Oncology, Biology, Physics|May 1, 2012
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lungMohan Suntharalingam, Rebecca Paulus, Martin J Edelman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2011
Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancerMartin J Edelman, Gregory Otterson, Joseph Leach, et al.
The Annals of Thoracic Surgery|October 7, 2004
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancerJoshua R Sonett, Mohan Suntharalingam, Martin J Edelman, et al.
Clinical Lung Cancer|October 16, 2012
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung CancerDavid R Spigel, Martin J Edelman, Tony Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|March 30, 2010
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancerJoseph Treat, Martin J Edelman, Chandra P Belani, et al.
Pageof 19